EP3656769A4 - ARYL-PHOSPHORUS-OXYGEN COMPOUND USED AS A KINASE EGFR INHIBITOR - Google Patents

ARYL-PHOSPHORUS-OXYGEN COMPOUND USED AS A KINASE EGFR INHIBITOR Download PDF

Info

Publication number
EP3656769A4
EP3656769A4 EP18834412.1A EP18834412A EP3656769A4 EP 3656769 A4 EP3656769 A4 EP 3656769A4 EP 18834412 A EP18834412 A EP 18834412A EP 3656769 A4 EP3656769 A4 EP 3656769A4
Authority
EP
European Patent Office
Prior art keywords
phosphorus
aryl
compound used
egfr inhibitor
oxygen compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP18834412.1A
Other languages
German (de)
French (fr)
Other versions
EP3656769B1 (en
EP3656769A1 (en
Inventor
Lingyun Wu
Xile LIU
Charles Z. Ding
Shuhui Chen
Lihong Hu
Lele ZHAO
Wei Pan
Guoping Hu
Jian Li
Ning Zhao
Jun Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of EP3656769A1 publication Critical patent/EP3656769A1/en
Publication of EP3656769A4 publication Critical patent/EP3656769A4/en
Application granted granted Critical
Publication of EP3656769B1 publication Critical patent/EP3656769B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65615—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing a spiro condensed ring system of the formula where at least one of the atoms X or Y is a hetero atom, e.g. S
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP18834412.1A 2017-07-19 2018-07-19 Aryl-phosphorus-oxygen compound as egfr kinase inhibitor Active EP3656769B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710592778 2017-07-19
CN201711277584 2017-12-06
CN201810130633 2018-02-08
CN201810355614 2018-04-19
PCT/CN2018/096344 WO2019015655A1 (en) 2017-07-19 2018-07-19 Aryl-phosphorus-oxygen compound as egfr kinase inhibitor

Publications (3)

Publication Number Publication Date
EP3656769A1 EP3656769A1 (en) 2020-05-27
EP3656769A4 true EP3656769A4 (en) 2021-04-14
EP3656769B1 EP3656769B1 (en) 2023-01-25

Family

ID=65015797

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18834412.1A Active EP3656769B1 (en) 2017-07-19 2018-07-19 Aryl-phosphorus-oxygen compound as egfr kinase inhibitor

Country Status (18)

Country Link
US (1) US11390625B2 (en)
EP (1) EP3656769B1 (en)
JP (1) JP7233410B2 (en)
KR (1) KR102647277B1 (en)
CN (3) CN113354685B (en)
AU (1) AU2018304757B2 (en)
CA (1) CA3069829A1 (en)
DK (1) DK3656769T3 (en)
ES (1) ES2938899T3 (en)
IL (1) IL272115B (en)
MX (1) MX2020000710A (en)
MY (1) MY198428A (en)
NZ (1) NZ760967A (en)
PH (1) PH12020550034B1 (en)
PL (1) PL3656769T3 (en)
SG (1) SG11202000470XA (en)
WO (1) WO2019015655A1 (en)
ZA (1) ZA202000395B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210287A (en) * 2018-11-01 2022-02-15 Syros Pharmaceuticals Inc CYCLIN DEPENDENT KINASE 7 (CDK7) INHIBITORS
JP2022517396A (en) * 2019-01-18 2022-03-08 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド EGFR inhibitor salt, crystalline form and method for producing it
WO2020200191A1 (en) * 2019-04-04 2020-10-08 Betta Pharmaceuticals Co., Ltd Egfr inhibitors, compositions and methods there of
CN113166103B (en) * 2019-04-26 2022-12-16 江苏先声药业有限公司 EGFR inhibitors and their applications
CN112513029B (en) * 2019-06-21 2023-10-24 上海翰森生物医药科技有限公司 Nitrogen-containing arylphosphorus oxide derivatives, preparation methods and applications thereof
CN114430739A (en) * 2019-07-26 2022-05-03 贝达药业股份有限公司 EGFR inhibitor, composition and preparation method thereof
WO2021018003A1 (en) * 2019-07-26 2021-02-04 贝达药业股份有限公司 Egfr inhibitor, composition, and preparation method therefor
CN114286678A (en) * 2019-08-23 2022-04-05 北京泰德制药股份有限公司 Compounds for inhibiting and inducing degradation of EGFR and ALK
CN112538072B (en) * 2019-09-21 2024-02-06 齐鲁制药有限公司 Aminopyrimidine EGFR inhibitors
CN112824420B (en) * 2019-11-21 2022-04-26 浙江同源康医药股份有限公司 Compounds useful as EGFR kinase inhibitors and uses thereof
CN114728932B (en) * 2019-11-29 2024-11-29 江苏先声药业有限公司 Polyarylates as EGFR kinase inhibitors
AU2021218497A1 (en) * 2020-02-14 2022-09-22 Betta Pharmaceuticals Co., Ltd Quinolyl phosphine oxide compound, and composition and application thereof
CN113717156B (en) * 2020-05-25 2023-05-09 南京红云生物科技有限公司 EGFR inhibitor, its preparation method and use
AU2021284676A1 (en) 2020-06-01 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. New pyrazine compound
WO2021244502A1 (en) * 2020-06-03 2021-12-09 江苏先声药业有限公司 Polyaryl compound and use
AU2021288300A1 (en) * 2020-06-08 2023-02-02 Hongyun Biotech Co., Ltd. Alkenyl pyrimidine compound, preparation method therefor, and application thereof
US20230248834A1 (en) * 2020-07-16 2023-08-10 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
WO2022012622A1 (en) * 2020-07-16 2022-01-20 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
CN116438172A (en) * 2020-11-13 2023-07-14 南京红云生物科技有限公司 HPK1 kinase regulator, its preparation method and application
CN114644654A (en) * 2020-12-18 2022-06-21 上海翰森生物医药科技有限公司 Oxidized aryl phosphorus derivative, acid salt or crystal form thereof, and preparation method and application thereof
WO2022127807A1 (en) * 2020-12-18 2022-06-23 江苏豪森药业集团有限公司 Crystal form of aryl phosphorus oxide derivative free base, preparation method therefor, and application thereof
KR20220097305A (en) * 2020-12-29 2022-07-07 주식회사 비투에스바이오 Heteroaryl derivative compounds, and uses thereof
TW202237597A (en) * 2021-03-19 2022-10-01 大陸商上海齊魯製藥研究中心有限公司 Novel degraders of egfr
IL307327A (en) * 2021-04-01 2023-11-01 Therapex Co Ltd Pyrimidine derivative having protein kinase inhibitory activity, and therapeutic pharmaceutical composition comprising same
KR102800635B1 (en) 2021-04-01 2025-04-29 주식회사 테라펙스 Pyrimidin derivatives as protein kinase inhibitors and pharmaceutical compositions for treating disease containing the same
WO2022208454A1 (en) 2021-04-02 2022-10-06 Bridge Biotherapeutics, Inc. N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof
JP7744155B2 (en) * 2021-04-19 2025-09-25 キヤノンメディカルシステムズ株式会社 Pluripotent stem cell manufacturing system
IL308103A (en) * 2021-04-30 2023-12-01 Xizang Haisco Pharmaceutical Co Ltd Phosphonyl derivative, and composition and pharmaceutical application thereof
CN117500813A (en) * 2021-06-17 2024-02-02 微境生物医药科技(上海)有限公司 Arylphosphine oxides
JP2024525181A (en) * 2021-06-21 2024-07-10 ベイジーン スウィッツァーランド ゲーエムベーハー (R)-Glutarimide CRBN Ligands and Methods of Use
TW202321228A (en) * 2021-08-06 2023-06-01 大陸商南京紅云生物科技有限公司 Benzodioxane compound, preparation method therefor and application thereof
CN117769560A (en) * 2021-08-19 2024-03-26 贝达药业股份有限公司 Salts, crystal forms and compositions and applications of EGFR inhibitors
CN114181159B (en) * 2021-12-28 2024-02-20 南通大学 2,4, 5-trisubstituted pyrimidine hydrazide derivative and preparation method and application thereof
CN118696038A (en) * 2022-01-18 2024-09-24 百济神州有限公司 Degradation of EGFR by conjugating EGFR inhibitors to E3 ligase ligands and methods of use thereof
CN117263982B (en) * 2022-06-21 2025-11-11 江苏豪森药业集团有限公司 Crystal form of nitrogen-containing aryl phosphorus oxide derivative, and preparation method and application thereof
WO2024005516A1 (en) * 2022-06-28 2024-01-04 보로노이 주식회사 Heteroaryl derivative compound and use thereof
CN115161284B (en) * 2022-07-04 2024-07-09 无锡多宁生物科技有限公司 LMH suspension cell resuscitating culture method and application thereof
WO2024072075A1 (en) 2022-09-30 2024-04-04 주식회사 테라펙스 Pyrimidine derivative having protein kinase inhibitory activity, and therapeutic pharmaceutical composition comprising same
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (en) 2023-05-04 2025-03-01 美商銳新醫藥公司 Combination therapy for a ras related disease or disorder
CN116655600B (en) * 2023-05-23 2025-08-22 江南大学 A substituted 2-arylaminopyrimidine compound, pharmaceutical composition and use thereof
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (en) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026026940A1 (en) * 2024-08-01 2026-02-05 石药集团中奇制药技术（石家庄）有限公司 Egfr degrader and preparation method therefor and use thereof
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051587A1 (en) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers
WO2012151561A1 (en) * 2011-05-04 2012-11-08 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2017086832A1 (en) * 2015-11-19 2017-05-26 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") Substituted n2-(4-amino-2-methoxyphenyl)-n4-[2-(dimethylphosphinoyl)-phenyl]-5-chloro-pyrimidine-2,4-diamines as alk and egfr modulators intended for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002479D0 (en) 1990-07-20 1990-07-20 Pharmacia Ab ANTIBODY CONJUGATES
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN105601573B (en) 2014-11-24 2021-07-02 中国科学院上海药物研究所 2-Aminopyrimidine compound and its pharmaceutical composition and application
KR101705980B1 (en) * 2015-06-12 2017-02-13 중앙대학교 산학협력단 Novel pazopanib derivatives and pharmaceutical composition comprising the same
CN105017160B (en) 2015-06-24 2017-12-29 温州医科大学 A kind of miazines EGFRT790MInhibitor and its synthetic method and application
CN106699810A (en) * 2015-11-17 2017-05-24 清华大学 Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity
RU2606951C1 (en) * 2015-11-19 2017-01-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Dichloroacetates of substituted n4-[2-(dimethylphosphoryl)phenyl]-n2-(2-methoxy-4-piperidin-1-ylphenyl)-5-chloropyrimidine-2,4-diamines as modulators of alk and egfr, intended for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051587A1 (en) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers
WO2012151561A1 (en) * 2011-05-04 2012-11-08 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2017086832A1 (en) * 2015-11-19 2017-05-26 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") Substituted n2-(4-amino-2-methoxyphenyl)-n4-[2-(dimethylphosphinoyl)-phenyl]-5-chloro-pyrimidine-2,4-diamines as alk and egfr modulators intended for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019015655A1 *

Also Published As

Publication number Publication date
EP3656769B1 (en) 2023-01-25
US20200207768A1 (en) 2020-07-02
ZA202000395B (en) 2023-06-28
NZ760967A (en) 2026-01-30
MX2020000710A (en) 2020-07-29
JP7233410B2 (en) 2023-03-06
CN110944989B (en) 2021-06-25
ES2938899T3 (en) 2023-04-17
SG11202000470XA (en) 2020-02-27
AU2018304757A1 (en) 2020-02-06
CN113354685B (en) 2022-12-20
KR20200032146A (en) 2020-03-25
EP3656769A1 (en) 2020-05-27
CA3069829A1 (en) 2019-01-24
MY198428A (en) 2023-08-29
DK3656769T3 (en) 2023-02-13
US11390625B2 (en) 2022-07-19
CN113354685A (en) 2021-09-07
PH12020550034B1 (en) 2024-05-22
CN110944989A (en) 2020-03-31
PH12020550034A1 (en) 2021-02-15
BR112020001124A2 (en) 2020-09-01
PL3656769T3 (en) 2023-03-27
CN113480575A (en) 2021-10-08
AU2018304757B2 (en) 2022-02-10
IL272115B (en) 2022-09-01
JP2020527151A (en) 2020-09-03
IL272115A (en) 2020-03-31
WO2019015655A1 (en) 2019-01-24
KR102647277B1 (en) 2024-03-12

Similar Documents

Publication Publication Date Title
EP3656769A4 (en) ARYL-PHOSPHORUS-OXYGEN COMPOUND USED AS A KINASE EGFR INHIBITOR
EP3719012A4 (en) URACIL COMPOUND USED AS A C-MET / AXL INHIBITOR
MA47460A (en) AMINOTRIAZOLOPYRIDINES USED AS KINASE INHIBITORS
EP3464275A4 (en) EGFR INHIBITOR COMPOUNDS
EP3533787A4 (en) PYRIDONE COMPOUND AS C-MET INHIBITOR
MA48994A (en) ISOQUINOLEINS USED AS HPK1 INHIBITORS
EP3697787A4 (en) HETEROCYCLIC COMPOUND FOR USE AS A PROTEIN KINASE INHIBITOR
MA47433A (en) QUINAZOLINE COMPOUND
MA51431A (en) OXY-FLUOROPIPERIDINE DERIVATIVES USED AS A KINASE INHIBITOR
MA51429A (en) AMINO-FLUOROPIPERIDINE DERIVATIVES USED AS A KINASE INHIBITOR
MA46091A (en) BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS
MA45244A (en) SUBSTITUTED PYRIDINES USED AS DNMT1 INHIBITORS
MA42990A (en) COMPOUNDS USEFUL AS IMMUNOMODULATORS
MA47013A (en) BENZOLACTAM COMPOUNDS USED AS KINASE PROTEIN INHIBITORS
MA51878A (en) AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS
EP3533796A4 (en) AMINO-PYRAZOLOPYRIMIDINE COMPOUND FOR USE AS A NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR
MA47576A (en) BICYCLIC OGA INHIBITOR COMPOUNDS
MA43862A (en) SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS ROCK INHIBITORS
MA40775A (en) 4- (4- (4-PHENYLUREIDO-NAPHTALÉN -1-YL) OXY-PYRIDIN-2-YL) AMINO-BENZOIC ACID USED AS A KINASE P38 INHIBITOR
MA43169A (en) HETEROCYCLIC COMPOUNDS USED AS PI3K-GAMMA INHIBITORS
KR20180084996A (en) A novel biphenyl compound or salt thereof
MA40587A (en) AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS
MA47420A (en) OGA INHIBITOR COMPOUNDS
EP3822276A4 (en) HETEROCYCLIC COMPOUND USED AS A TRK INHIBITOR
SI3672965T1 (en) A pyrimidine compound as a JAK-KINASE inhibitor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210315

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/12 20060101AFI20210309BHEP

Ipc: A61K 31/675 20060101ALI20210309BHEP

Ipc: A61K 31/505 20060101ALI20210309BHEP

Ipc: A61P 35/00 20060101ALI20210309BHEP

Ipc: A61K 31/506 20060101ALI20210309BHEP

Ipc: C07D 239/48 20060101ALI20210309BHEP

Ipc: C07D 401/14 20060101ALI20210309BHEP

Ipc: C07D 403/12 20060101ALI20210309BHEP

Ipc: C07D 409/04 20060101ALI20210309BHEP

Ipc: C07D 417/14 20060101ALI20210309BHEP

Ipc: C07D 471/06 20060101ALI20210309BHEP

Ipc: C07F 9/6512 20060101ALI20210309BHEP

Ipc: C07F 9/6558 20060101ALI20210309BHEP

Ipc: C07D 409/14 20060101ALI20210309BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220908

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20230209

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1545845

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230215

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018045818

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2938899

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20230417

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230525

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230425

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230525

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230426

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018045818

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20231026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230719

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1545845

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230125

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250612

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250612

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250613

Year of fee payment: 8

Ref country code: BE

Payment date: 20250619

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250610

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20180719

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250610

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20250610

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20180719

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250804

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250611

Year of fee payment: 8

Ref country code: DK

Payment date: 20250714

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250708

Year of fee payment: 8

Ref country code: IT

Payment date: 20250623

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20250625

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250801

Year of fee payment: 8